[
    [
        {
            "time": "",
            "original_text": "同质化创新受打击，药明康德震荡，贝达药业跌跌不休「基因测序周评榜」",
            "features": {
                "keywords": [
                    "同质化创新",
                    "药明康德",
                    "贝达药业",
                    "基因测序"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "基因测序"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "同质化创新受打击，药明康德震荡，贝达药业跌跌不休「基因测序周评榜」",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]